Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and radiation in pancreatic cancer
NCT02207465Phase 1Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Jul 2014
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Abramson Cancer Center. Started Jul 2014; status: active, not recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02207465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207465.